Marginal Zone Lymphoma

2-Year PFS Can Predict Outcomes in Patients With Marginal Zone Lymphomas

12/02/2018

Researchers have confirmed the prognostic role of 2-year PFS in patients with MZLs, according to a study presented at ASH 2018.

Researchers have confirmed the...

12/02/2018

Oncology

News

Triplet Therapy Yields Promising Results in Untreated FL and MZL

12/02/2018

Treatment-naïve patients with FL and MZL tolerated and responded well to ibrutinib plus rituximab and lenalidomide, according to a recent phase 2 trial presented at ASH 2018.

Treatment-naïve patients with FL...

12/02/2018

Oncology

Ofatumumab Promising in Elderly Patients With Relapsed/Refractory Splenic MZL

11/30/2018

Preliminary results from an ongoing clinical trial presented at ASH 2018 suggest that elderly patients with splenic MZL respond more favorably to ofatumumab than to rituximab.

Preliminary results from an...

11/30/2018

Oncology